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Abstract 
Background: Concurrent malaria and dengue infection is frequently diagnosed in endemic countries, but its 
immunopathology remains largely unknown. In the present study, a large panel of cytokines/chemokines and clinical 
laboratory markers were measured in patients with Plasmodium vivax and dengue co‑infection as well as in individu‑
als with malaria or dengue mono‑infections in order to identify biosignatures of each clinical condition.
Methods: Individuals from the Brazilian Amazon were recruited between 2009 and 2013 and classified in three 
groups: vivax malaria (n = 52), dengue (n = 30) and vivax malaria and dengue co‑infection (n = 30). P. vivax malaria 
was diagnosed by thick blood smear and confirmed by PCR; dengue cases were detected by IgM ELISA or NS1 pro‑
tein. The plasma levels of cytokines and chemokines were determined by multiplex assay.
Results: Individuals with malaria and dengue co‑infection displayed lower levels of platelets and haemoglobin than 
those with malaria or dengue mono‑infections (p = 0.0047 and p = 0.0001, respectively). The group of individuals co‑
infected exhibited the highest median concentrations of IFN‑γ, IL‑6, CCL4 than the mono‑infected groups. Network 
analyses of plasma cytokines/chemokines revealed that malaria and dengue co‑infection exhibits a distinct immune 
profile with critical roles for TNF, IL‑6 and IFN‑γ. Further, parasitaemia levels displayed positive significant interactions 
with IL‑6, CCL4 and IL‑10 in the group of patients co‑infected with malaria and dengue. No differences were observed 
in distribution of dengue virus serotypes and Plasmodium parasitaemia levels between the groups.
Conclusions: The findings described here identify unique patterns of circulating immunological markers in cases of 
malaria and dengue co‑infection and provide insights on the immunopathology of this co‑morbid condition.
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Background
Malaria and dengue fever are the most frequent arthro-
pod-borne diseases in the world. Every year Plasmodium 
infection is responsible for around one million deaths, 
mainly in children [1]. It is estimated that two-fifths of 
the world population are at risk of dengue fever with 
50–100 million cases each year worldwide [2, 3]. Both 
malaria and dengue fever exhibit dramatically similar 
geographic distribution (mostly in tropical and sub-tropi-
cal regions) and the detection of patients with concurrent 
malaria and dengue infections is not rare [4–19].
Previous studies have reported a frequent presence of 
malaria and dengue co-infections in different countries 
and implied that this fact creates challenges for reliable 
clinical diagnosis due to the overlap of major symptoms 
with malaria or dengue mono-infections [4, 6–8, 11, 
12, 14, 16]. Recently, observations from a case series of 
patients with dual malaria and dengue infections per-
formed at the Brazilian Amazon indicated that co-
infection can potentially result in a more severe disease 
presentation [10]. The status of host immune activation 
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profile in patients with dengue and malaria co-infection, 
which may explain the clinical features of this condition, 
has not been systematically investigated.
The immunopathogeneses of dengue and malaria display 
common features, which include the production of multiple 
cytokines and the balance between pro-inflammatory and 
anti-inflammatory responses may regulate the clinical spec-
trum of these infections [20–25]. Importantly, circulating 
cytokines as well as other inflammatory mediators may be 
used as biomarkers for an early diagnosis or for prediction 
of unfavourable clinical deterioration and poor prognosis 
or treatment responses [26]. Moreover, understanding the 
key factors associated with increased morbidity may lead to 
development of host-directed therapy focused on the mod-
ulation of pathological immune responses and better clini-
cal prognosis. The present study performs for the first time 
a detailed exploratory description of the systemic immune 
profile of individuals presenting with Plasmodium vivax 
malaria and dengue co-infection as well as in subjects with 
P. vivax or dengue mono-infections.
Methods
Study design and participants
Outpatients with an acute febrile syndrome who sought 
care in a reference hospital (Fundação de Medicina 
Tropical Doutor Heitor Vieira Dourado, FMT-HVD) 
in Manaus, in the Brazilian Amazon, were recruited 
between 2009 and 2013. Malaria individuals were diag-
nosed by blood thick smear and those with P. vivax con-
firmed by PCR were recruited. Dengue subjects were 
diagnosed by: NS1 and RT PCR (Kit Platelia™ Den-
gue NS1 Ag, Bio-Rad, France) in individuals with fewer 
than 6  days of fever, or by the detection of IgM ELISA 
as descrided by Kuno et al. [27] in individuals with more 
than 7 days of fever. All dengue-positive individuals were 
recruited and had the identification of virus serotype by 
RT PCR. Co-infected subjects with P. vivax malaria and 
dengue were also recruited. All patients with microscopic 
or molecular diagnosis of malaria caused by Plasmodium 
falciparum or P. vivax and P. falciparum co-infection 
(mixed infection), patients with serologic diagnosis of 
viral hepatitis (A, B, C, and D), HIV, and leptospirosis 
were excluded. Patients with complications of dengue or 
malaria according to WHO criteria [28] were excluded 
from this study. All malaria cases were treated follow-
ing the guidelines of the National Foundation of Health, 
Brazil, with chloroquine for three days and primaquine 
(0.5 mg/kg/day) for 7 days. Dengue patients were treated 
according to their symptomatology. No individuals were 
treated for malaria or/and dengue 30  days before the 
blood collection and participation in this study.
Ethics statement
All clinical investigations were conducted according to 
the principles expressed in the Declaration of Helsinki. 
Written informed consent was obtained from all par-
ticipants before enrolling into the study. This study was 
approved by the Ethics Committee of the FMT-HVD 
(protocol numbers: 2009/15243 and 39163/2012).
Plasma measurements
Blood was obtained by venopuncture at the study enrol-
ment and heparinized plasma was separated by centrifu-
gation and stored at −70  °C until use in immunoassays. 
Circulating levels of several cytokines and chemokines, 
including IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, 
IL-12p70, IL-13, IL-17, IFN-γ, TNF, CCL2, CCL4, GCSF, 
GMCSF, were measured using a single multiplex assay 
according to the manufacturer’s protocol (BIO-RAD, 
Hercules, CA, USA). The clinical laboratory markers 
haemoglobin (HB), haematocrit (HT), platelets (PTL), 
aspartate amino-transferase (AST) and alanine amino-
transferase (ALT) were measured in fresh plasma/serum 
samples at the Clinical Laboratory facility from the FMT-
HVD (Manaus, Brazil).
Network analysis
The inferential networks were generated from Spear-
man correlation matrices containing values of each 
biomarker measured in the plasma samples. The val-
ues were input in JMP 10.0 software (SAS, Cary, NC, 
USA). Each mediator is selected as a target, and the 
software performs a search within the other media-
tors for those that are correlated, with the target cal-
culating a correlation matrix using Spearman rank 
tests. As a result, the features related to the selected 
target are linked. The links shown in the networks rep-
resent statistically significant Spearman rank correla-
tions (P < 0.05). In order to analyse the structure of the 
biomarker networks, the network density was calcu-
lated, which is, in the context of this study, the ratio 
of the number of edges inferred in the network over 
the total number of possible edges between all pairs of 
nodes [24]. The density measure is defined as follows: 
density =  L/(N (N −  1)/2), in which L is the number 
of observed edges (i.e., Spearman correlations with 
P < 0.05) and N is the total number of the nodes in the 
network. The density is normalized, ranging between 0 
(no edges in the network) and 1 (all possible edges pre-
sent). The networks figures were customized using the 
Ingenuity Systems Pathway Analysis software (Ingenu-
ity Systems, Redwood City, CA, USA) and Adobe Illus-
trator (Adobe Systems Inc.).
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Data analysis
In the exploratory analysis of the data, frequency tables 
were constructed and the Chi square test was applied to 
evaluate the association between categorical variables. 
The continuous variables were tested for Gaussian dis-
tribution within the total sample using D’Agostino and 
Pearson omnibus normality test. All variables were not 
under normal distribution, and non-parametric tests 
were used instead. In this context, Kruskal–Wallis with 
Dunn’s multiple comparison (when three groups were 
compared) or Mann–Whitney tests (when two groups 
were compared) were used to assess the differences 
between the clinical groups. Multinomial regression 
analyses adjusted for age and gender were performed to 
test associations between the laboratory measures (below 
or above the median values of the entire study popu-
lation) and the different clinical conditions evaluated 
(malaria, dengue or co-infection). A hierarchical cluster 
analysis using the Ward’s method was performed to test 
if a combination of different immune-related biomarkers 
could cluster the study groups separately. The statistical 
analyses were performed using the programs GraphPad 
Prism 6.0 (GraphPad Software Inc., USA), SPSS 19.0 
(IBM, Armonk, NY, USA) and JMP 11.0 (SAS, Cary, NC, 
USA). A p value lower than 0.05 was considered statisti-
cally significant.
Results
Characteristics of the study participants
After clinical and microbiological assessments, indi-
viduals were grouped as vivax malaria (n = 52), dengue 
(n = 30) and co-infected vivax malaria/dengue (n = 30). 
Most participants from the malaria group were male 
(80.77  %, n  =  42) while the groups of co-infected and 
dengue patients exhibited a predominance of females 
(70.00  %, n  =  9 for both; p  <  0.0001). There were no 
differences with regard to age between the groups 
(p = 0.0724; Table 1) and also no statistically significant 
discrepancy in parasitaemia levels between the groups of 
individuals infected with P. vivax (p =  0.4912; Table  1). 
Moreover, the majority of individuals infected with den-
gue had DENV2 serotype with no differences in distribu-
tion of virus serotypes in the groups of individuals with 
dengue or dengue and malaria co-infection (Table 1).
Differential expression of clinical laboratory parameters 
reveals unique patterns of associations with infection 
status
Univariate analyses revealed that individuals co-infected 
with malaria and dengue exhibited lower levels of HB and 
PTL than those with malaria or dengue mono-infections 
(p =  0.0047 and p =  0.0001, respectively; Table  1). On 
the other hand, plasma AST levels were elevated whereas 
ALT concentrations were decreased in individuals with 
malaria mono-infection compared to those with dengue 
or co-infection (p = 0.0186 and p < 0.0001, respectively; 
Table  1). Multinominal regression analyses adjusted 
for age and gender uncovered that higher levels of HB 
(adjusted OR: 23.344 95 % CI 2.534–215.023, p = 0.005) 
and PTL (adjusted OR: 8.065 95  % CI: 1.527–42.612, 
p = 0.014) were associated with dengue when compared 
to malaria (Fig.  1). Furthermore, higher levels of HB 
(adjusted OR: 6.264 95  % CI 1.535–25.553, p  =  0.011) 
and PTL (adjusted OR: 21.471 95  % CI 3.077–149.827, 
p = 0.002) were associated with dengue mono-infection 
compared with dengue and malaria co-infection (Fig. 1). 
Higher levels of AST (unadjusted OR: 3.030 95  % CI 
1.160–7.914, p = 0.024) and low levels of ALT (adjusted 
OR: 0.219 95 % CI 0.069–0.695, p = 0.010) were associ-
ated with malaria mono-infection compared with the 
malaria/dengue co-infection condition (Fig. 1).
Networking the immune response
A panel of 17 cytokines and chemokines was used to 
build networks demonstrating the interactions between 
the candidate biomarkers in each group (Fig.  2a). The 
distributions of plasma concentrations of each cytokine 
or chemokine amongst the different clinical groups are 
provided (see Additional file  1). The network analysis 
revealed an absence of negative correlations between 
the candidate biomarkers in each one of the clinical 
groups and only statistically significant positive correla-
tions were detected (Fig.  2a). Strikingly, the densities of 
the networks from each clinical group were dramatically 
different (Fig. 2a). The group of malaria mono-infection 
exhibited highest density of interactions (network den-
sity: 0.661) followed by the groups of co-infected patients 
(network density: 0.4338) and dengue mono-infection 
(network density: 0.147) (Fig. 2a). P values and Spearman 
rank values for each correlation between the immune 
biomarkers according to study groups are detailed (see 
Additional file  2). Moreover, the simultaneous assess-
ment of several immune-related markers revealed rela-
tive differences in plasma concentrations that resulted 
in unique biosignatures, which could highlight differ-
ences between the study groups in an hierarchical cluster 
analysis (Fig. 2b). Amongst the clinical groups evaluated, 
the group of individuals with malaria and dengue co-
infection exhibited the highest median concentrations of 
IFN-γ, IL-6, CCL4 (Fig. 2b). The group of malaria mono-
infected patients exhibited a biosignature composed by 
higher levels of IL-10 and CCL2 whereas the group of 
dengue mono-infected individuals displayed a signature 
with high expression of IL-4, IL-7 and Il-12 in plasma 
(Fig. 2b). Furthermore, TNF was found elevated in both 
groups of malaria mono-infection and co-infection with 
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Table 1 Demographic characteristics and laboratory measures of the participants
IQR interquantile range.
a Categorized variables were compared using Chi square test or Fisher exact test.
b Continuous variables were compared using Mann–Whitney for two groups or Kruskal–Wallis test with Dunn’s multiple comparison test for three groups or more.
Malaria Co-infection Mal/ 
Deng
Dengue P value




Male‑no. (%) 42 (80.77) 09 (30.00) 09 (30.00) <0.0001a <0.0001a 1.000a
Median (IQR) age 
(year)
36.00 (26.25–43.75) 31.11 (20.80–44.74) 42.50 (30.00–52.25) 0.0724b 0.4471b 0.0574b
Median (IQR) of  
parasitaemia  
(parasites/uL)
3,022 (985.2–9,313) 4,262 (1,595–12,199) – – 0.4912b –
Dengue serotypes‑no. (%)
 DENV1 3 (10.00) 1 (3.33) – – 0.2247a
 DENV2 18 (60.00) 21 (70.00)
 DENV3 1 (3.33) 4 (13.33)
 DENV4 8 (26.67) 4 (13.33)
Median of laboratory measures (IQR)
 Haemoglobin  
(g/dL)
13.20 (12.50–14.20) 12.95 (11.90–14.45) 15.00 (13.40–15.95) 0.0047b 0.4819b 0.0038b
 Haematocrit (%) 43.35 (40.43–45.98) 42.05 (37.80–45.98) 43.90 (40.65–46.90) 0.5803b 0.3732b 0.3817b
 Platelets (by mm3) 102,000 (65,000–
131,500)
87,500 (59,000–114,250) 186,500 (124,000–
229,750)
0.0001b 0.1079b <0.0001b
 AST (IU/L) 67.50 (50.00–91.00) 47.00 (31.50–72.50) 47.00 (28.00–147.00) 0.0186b 0.0048b 0.9315b
 ALT (IU/L) 33.00 (20.00–49.75) 69.00 (46.00–95.50) 67.00 (29.50–119.00) <0.0001b  < 0.0001b 0.9043b





































univariate adjusted for age and gendermodel:
denguemalaria denguecoinfection malariacoinfection
Marker OR and 95% CI OR and 95% CI OR and 95% CIP-value P-value P-value
associations with clinical group
0.001 0.01 0.1 1 10 100 1000 0.001 0.01 0.1 1 10 100 1000 0.001 0.01 0.1 1 10 100 1000
Fig. 1 Discrimation of malaria, dengue and co‑infection groups by laboratory measures. Differentiation between dengue vs malaria, dengue vs 
co‑infection and malaria vs co‑infection groups were done by laboratory measures—HB haemoglobin, HT haematocrit, PTL platelets, AST aspartate 
aminotransferase, ALT alanine aminotransferase—through multinominal regression analysis with calculation of odds ratios (OR) and 95 % confi‑
dence intervals (CI), represented by the icons and bars, respectively (a). Red icons represent OR adjusted for age and gender and blue icons were 
unadjusted (univariate) (a).
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Fig. 2 Networks of candidate immune‑related biomarkers during malaria, dengue or co‑infection. Plasma levels of several immune‑related 
(cytokines, chemokines) biomarkers were measured in malaria, dengue and co‑infection subjects. Each connecting line represents a significant 
interaction (P < 0.05) detected by Spearman’s correlation test (a). All interactions had positive correlations. A heat map was designed to depict the 
overall pattern of expression of immune markers in the different outcomes by the median value of each parameter (b). A two‑way hierarchical clus‑
ter analysis (Ward’s method) of immune molecules by clinical group was performed (b). Biomarkers that had the same median in the three groups 
were excluded from the heat map and cluster analysis. The colours shown for each symbol represent the fold variation from the median values 
calculated for each marker (a, b). The distribution of haemoglobin (HB), haematocrit (HT), platelets (PTL), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT) in different clinical groups is shown in red symbols (medians and interquartile ranges) whereas the values for network 
densities are shown as black bars (c). The variation of HB, HT, PTL, AST, and ALT according to the groups was assessed using the Kruskal–Wallis test 
(***P < 0.001; **P < 0.01; *P < 0.05; ns = non‑significant) (c). The five immune‑related biomarkers with the highest number of interactions in all three 
groups were chosen (IFN‑γ, IL‑6, IL‑13, TNF, and IL‑12) and the relative number of interactions of these biomarkers was calculated according to each 
group (d). Dark grey rectangles represent the highest relative number of connections, light grey rectangles the medium relative number and white 
rectangles the lowest relative number of hits between molecules (d).
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dengue whereas IL-13 was detected in higher amounts 
in the groups of dengue mono-infection and co-infection 
(Fig.  2b). While investigating the relationships between 
changes in clinical laboratory markers and the inflam-
matory environment assessed by network densities, it 
was observed that HB, PTL and ALT displayed a general 
trend to decrease in concentration values according to 
the increase of network’s complexities (Fig.  2c). Never-
theless, AST levels tended to increase following the den-
sity of correlations between the markers in the groups 
(Fig. 2c). No significant difference was observed in varia-
tions of HT levels and its associations with network den-
sities (Fig. 2c).
Amongst the 17 immune-related biomarkers assessed 
in the network analyses, five cytokines exhibited the 
highest number of interactions (statistically significant 
Spearman correlations) when all the study groups were 
considered together: IFN-γ (participated in 7.40  % of 
all interactions), IL-6 (8.88  % of all interactions), IL-13 
(7.10  % of all interactions), TNF (6.50  % of all interac-
tions) and IL-12p70 (6.50 % of all interactions) (Fig. 2d). 
In order to assess if the number of network connections 
involving each one of these five cytokines could highlight 
differences between the clinical groups, the percentage of 
edges involving with each molecule related to the overall 
number of edges in the network was calculated. Interest-
ingly, IFN-γ, IL-6 and IL-13 displayed the highest relative 
number of network interactions in the group of dengue 
mono-infected patients, whereas IL-12p70 exhibited the 
highest relative number of interactions in the malaria 
mono-infection group (Fig. 2d). TNF exhibited the high-
est number of interactions in the group of patients with 
malaria and dengue co-infection (Fig.  2d). These results 
argue that unique immune signatures involving plasma 
cytokine levels are able to highlight differences that dis-
tinguish malaria, dengue or dual malaria and dengue 
infection.
The next step was to uncover the interactions between 
clinical laboratory markers and the immune-related mol-
ecules. In all the study groups, HB exhibited positive 
associations with HT whereas ALT exhibited positive 
correlations with AST (Fig. 3a). It was found that HB and 
HT displayed several negative significant interactions 
mainly with IL-4, IL-5, IL-12p70, and IL-17, whereas ALT 
interacted negatively with IL-4 and IL-7 in the malaria 
group (Fig. 3a). In the group of patients with malaria and 
dengue co-infection, HB and HT displayed negative asso-
ciations with IL-7, whereas AST exhibited positive inter-
actions with CCL2, IL-13 and IL-8 (Fig. 3a). Noteworthy, 
it was observed that only in the dengue mono-infection 
group did PTL display interactions with immune mark-
ers (positive interactions with GMCSF, GCSF and IL-8), 
suggesting a major role for this molecule in this group 
(Fig.  3a). Furthermore, AST and ALT displayed nega-
tive associations with TNF in the network of the dengue 
mono-infection group (Fig.  3a). In the P. vivax-infected 
groups, the associations between parasitaemia and 
the immune markers were also studied (Fig.  3b). It was 
observed that P. vivax parasitaemia displayed positive 
significant interactions with IL-6, CCL4 and IL-10 in the 
group of patients co-infected with malaria and dengue, 
while this parameter exhibited several positive correla-
tions with many immune markers (GCSF, CCL2, CCL4, 
TNF, IL-12p70, IL-10, IL-6, and IL-4) in the group of 
malaria mono-infected subjects, suggesting a major role 
for parasitaemia in the immune profile in this clinical 
condition (Fig.  3b). P values and Spearman rank values 
for each correlation between the immune biomarkers 
and laboratory measures or parasitaemia are provided 
(see Additional file 3).
Discussion
Malaria or dengue immunology has been studied exten-
sively in a diverse range of scenarios, however, the pro-
file of the immune responses in individuals co-infected 
with Plasmodium and dengue virus has not been system-
atically explored. In the present study, a large panel of 
cytokines and chemokines as well as several clinical lab-
oratory markers used to assess degree of disease sever-
ity and inflammation-driven tissue damage have been 
investigated in plasma samples of patients with malaria, 
dengue or co-infection in order to identify immune sig-
natures associated with each infection status. Network 
analyses revealed that cases of malaria and dengue co-
infection exhibit a unique immune profile with a special 
role for TNF, IL-6, IFN-γ, and IL-7. In addition, the anal-
ysis herein further revealed a signature profile in which 
P. vivax parasitaemia levels display positive significant 
interactions with IL-6, CCL4 and IL-10 in patients with 
this co-infection, which was not observed in malaria 
mono-infected individuals.
Some studies have studied laboratory measurements 
in subjects with dual malaria and dengue infections [4, 
6, 11]. HB and PTL are usually shown to be decreased in 
individuals co-infected with malaria and dengue and AST 
has been shown to be higher in individuals with malaria 
compared with co-infected cases [4, 6, 11]. These findings 
are similar to the results described in the present study. 
When dengue was compared to malaria mono-infection 
or co-infected cases, the former had higher values of 
HB and PTL. Malaria infection is frequently associated 
with anaemia as its causative parasite has a blood stage 
and causes intense intravascular haemolysis. One major 
complication associated with both dengue and malaria 
disease is thrombocytopaenia and the findings from the 
present study indicate that P. vivax infection may cause 
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more severe thrombocytopaenia (with lowest values 
in co-infected cases) compared to dengue fever mono-
infection [29–31]. Other studies have also reported 
that platelet counts were lower in malaria patients than 
dengue patients [15, 32]. On the other hand, laboratory 
markers assessed in the current study showed similar 
values between malaria mono-infection and cases of 
malaria and dengue co-infection, with a major difference 
in ALT levels (and in less extension to AST), which were 
more elevated in the patients with co-infection, and no 
significant difference was observed in parasitaemia lev-
els. The relationship of AST and ALT and parasitaemia 
with clinical manifestations of mono- or co-infection 
of malaria and dengue is not well established. A previ-
ous study showed higher levels of AST and ALT and 
parasitaemia in malaria mono-infection compared to 
malaria and dengue co-infection [11]. Nevertheless, 
another report showed no differences in concentrations 
of AST and ALT as well as levels of parasitaemia between 
malaria mono-infected patients and those with malaria 
and dengue co-infection [6]. Differences in patient popu-
lations and parasite strains could explain these discrep-
ancies. Parasitaemia levels may have an important role in 
predicting hepatic damage and need to be considered in 
malaria-infected subjects [25].
Heightened levels of TNF and IFN-γ have been sys-
tematically associated with increased clinical disease 
severity in malaria or dengue fever in many case series 
[20, 21, 24, 25, 33–35]. An important role for TNF and 
IFN-γ in the onset of malaria symptomatology as well as 
in pathological processes associated with platelet con-
sumption, endothelial cell activation and haemorrhagic 
manifestations during dengue fever have been described 
previously [33, 36]. In the present study, increased TNF 
levels observed in the group of patients with malaria 
and dengue co-infection compared to malaria or den-
gue mono-infections, together with the significantly 




































































































Fig. 3 Associations between laboratory parameters, parasitaemia and immune‑related biomarkers. Statistically significant correlations between 
laboratory markers (a) or parasitaemia (b) and immune‑related biomarkers are shown for the different groups. The correlations were assessed using 
the Spearman rank test. The interactions involving parasitaemia shown in (c) are plotted on top of the host interactome. Green lines represent nega‑
tive significant (P < 0.05) correlations and orange lines, positive significant correlations.
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networks, argue that this cytokine may play a critical role 
in the pathogenesis of malaria and dengue fever comor-
bid condition. Noteworthy, TNF polymorphisms are 
common and may play a role in TNF levels in the context 
of malaria [37]. Moreover, amongst the clinical groups 
assessed herein, cases of malaria and dengue co-infection 
also exhibited the highest values of IFN-γ and IL-6. IL-6 
has been implicated in the pathogenesis of severe cases of 
dengue as this cytokine enhances the production of anti-
platelet or anti-endothelial cell auto-antibodies, as well 
as the induction of tissue plasminogen activator, leading 
to increased risk for bleeding [38, 39]. These findings on 
immune markers support the idea that co-infected cases 
may present with a more severe inflammation milieu and 
disease status compared to malaria or dengue mono-
infections. Recently, it has been described that individu-
als with concurrent dengue fever and malaria from the 
Brazilian Amazon and French Guiana exhibited more 
severe disease clinical presentation than mono-infections 
[6, 9, 10].
In the present study, plasma levels of IL-4, IL-7, IL-
12p70, and IL-13 were more elevated in subjects purely 
with dengue fever than in those with malaria mono-
infection or malaria and dengue co-infection. Note-
worthy, IL-12p70 has been previously associated with 
severity and protection during malaria [40–43], also 
polymorphism in this gene can influence this cytokine 
production during malaria [44]. IL-12p70 had the high-
est number of interacions in the malaria group and seems 
to influence the inflammatory milieu in this group. In 
addition, IL-13 had the highest relative number of inter-
actions in the cytokine/chemokine network of the group 
of dengue mono-infection. IL-4 and IL-13 plasma levels 
were also previously found to be higher in dengue fever 
compared to malaria cases [23]. The increase in plasma 
expression of Th2 cytokines (i.e., IL-4, IL-13) may be 
associated with augmentation of vascular permeability 
and vascular leakage as seen in dengue haemorrhagic 
fever [45, 46]. Regarding malaria mono-infection, IL-10 
and CCL2 were the immune markers with more relevant 
elevations in plasma. Maneekan et al. have described that 
IL-10 was statistically higher in malaria patients than 
in those with dengue fever [23]. Furthermore, IFN-γ/
IL-10 ratio has been reported to increase proportionally 
to malaria clinical severity [25], and it is possible that 
cases of malaria and dengue co-infection presenting with 
lower levels of IL-10 and higher levels of IFN-γ may be 
reflected in an increased disease severity. Further studies, 
including a broader clinical spectrum of the infections 
explored here, are necessary to address this question. In 
a study about the immune profile of dengue fever and 
parvovirosis, high levels of CCL2 tended to be associ-
ated with parvovirus B19 infection as the same way as 
observed herein with malaria infection [47]. Therefore, 
different infectious agents disease may stimulate specific 
features of the host immune responses, which may result 
in unique immune signatures.
Although the group of individuals co-infected with 
malaria and dengue displayed an intermediate density 
of the immune network compared to the other clinical 
groups, this group displayed the lowest values of HB and 
PTL, thus indicating that the relationships between the 
inflammatory markers may not be influenced directly by 
the levels of these clinical laboratory markers. However, a 
potential role for HB and HT in regulation of the inflam-
matory environment in malaria and dengue comorbidity 
could not be entirely discarded, and the network find-
ings indicate that these parameters were negatively cor-
related with IL-7 in this group. It has been reported that 
IL-7 plays an important role in CD4+ T cell immune 
responses against the dengue virus and this cytokine 
is also useful for maintaining the growth and antigen-
specific cytotoxic activity of CD4+ human cytotoxic T 
lymphocyte clones [48]. In addition, AST seemed to be 
highly influenced by immune molecules in the malaria 
and dengue co-infected patients as this enzyme was posi-
tively correlated with CCL2, IL-13 and IL-8.
In the context of laboratory and immune markers 
correlations, the group of individuals presenting with 
malaria mono-infection displayed significant nega-
tive correlations between ALT and IL-4 and IL-7. Liver 
enzymes are highly inducible by the activation of immune 
responses and ALT was also correlated with TNF and 
superoxide dismutase-1 (SOD-1) levels in another case 
series of vivax malaria [49]. Furthermore, HB and HT 
had several negative interactions with inflammatory 
mediators (IL-17, IL-12, IL-5, IL-4) in the malaria group. 
These interactions may be explained as HB and HT levels 
as well as the immune response are directly influenced by 
intravascular haemolysis of red blood cell rupture upon 
Plasmodium sp. replication. Noteworthy, PTL positively 
interacted with immune markers (GCSF, GMCSF and 
IL-8) only in the group of patients with dengue mono-
infection. It has been reported that exposure of mono-
cytes from healthy volunteers to platelets from patients 
with dengue induced the secretion of IL-8 [50]. Throm-
bocytopaenia is often described in dengue fever (about of 
23.6 % of cases) and it may play a role along with immune 
mediators in dengue immunopathology [51].
Parasitaemia was not different between the groups of 
individuals with malaria mono-infection and malaria 
and dengue co-infection, similarly to previous stud-
ies [6]. However, the network analysis uncovered that 
parasitaemia displayed more statistically significant 
interactions with cytokines/chemokines in the malaria 
mono-infection than in the group of co-infected patients. 
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The immune response of individuals with concurrent 
dengue and malaria infections is also influenced by den-
gue viruses and this may explain the lower number of 
interactions of parasitaemia in this group. Moreover, 
one limitation of the present report was that some co-
infected individuals could have had undiagnosed asymp-
tomatic malaria, which can sometimes be diagnosed only 
with molecular methods. It is well described that asymp-
tomatic malaria individuals control parasitaemia to very 
low levels (sometimes only detectable by molecular tech-
niques) and this clinical immunity results in a reduced 
intensity of the inflammatory response when compared 
to symptomatic malaria cases [24, 25].
Conclusion
Altogether, the findings of the present study indicate that 
concurrent malaria and dengue infections may cause 
a more severe disease compared to mono-infections 
as observed by laboratory and immune markers pro-
files. Overall, malaria and dengue co-infection displayed 
lower levels of platelets and haemoglobin and a specific 
immune signature with a special role for TNF compared 
to dengue or malaria. This detailed description of the 
immune response profile in subjects with malaria and 
dengue fever co-infection and the results depicted herein 
shed light into the immunopathology of this comorbid 
condition. Further prospective studies with larger sam-
ples and experimental models would be necessary to 
investigate the key mechanisms resulting in the biosigna-
tures identified here in patients with malaria and dengue 
co-infection.
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